Pro-Life Group Urges Removal of RU-486 from the Market

“No less than five women have died as a direct result of using this drug, yet the FDA seems content to continue ‘dialoguing’ about how to handle this ‘situation,’ while abortionists continue to prescribe this hazardous drug to unsuspecting women,” stated Stephen G. Peroutka, Esq., NPLAC chairman, regarding the meeting to be held jointly with the Centers for Disease Control (CDC), and the National Institute of Allergy and Infectious Diseases at the CDC’s Atlanta campus, which will focus on scientific questions about the infection Clostridium sordellii, that has led to the death of several women taking the chemical abortion regimen . “As far as RU-486 is concerned, the FDA’s initial failure occurred when the agency approved this drug for use; if the agency neglects to take immediate and decisive action to remove this deadly substance from the market, it will have utterly failed its mandate to act in the best interest of the public health and safety.”

“At a time when the integrity and efficacy of the FDA is under increased scrutiny for allegations of preferential treatment in the approval process, financial improprieties and other abuses of the regulatory system, it would be in the best interest of the agency to properly redress this problem,” said Schenck. Schenck’s comments are in response to recent revelations that the former FDA director is under criminal investigation for misconduct and questions surrounding the fast-track approval of several prescription drugs that were later removed from the market because they proved too dangerous for use.

“If the FDA were serious about this tragedy, they would admit their mistake, remove the drug from the market and take a serious look at the medical research—like that of Dr. Donna Harrison, chairman of the subcommittee on Mifeprex of AAPLOG—that clearly demonstrates that this drug is responsible for an exponentially higher number of deaths than originally believed,” concluded Peroutka.

Source: Press Release